Bio-Techne Corporation (NASDAQ:TECH) reported second-quarter fiscal 2026 results that showed steady revenue but stronger profitability, with adjusted earnings per share rising 10% year on year and beating market expectations.
The company posted adjusted EPS of $0.46 for the quarter, up from $0.42 a year earlier and ahead of the analyst consensus of $0.43. Shares were little changed in after-hours trading following the release.
Quarterly revenue totaled $295.9 million, flat compared with the prior year but above analysts’ forecasts of $290.42 million. Despite the lack of top-line growth, Bio-Techne delivered improved earnings as productivity gains and cost-control measures lifted its adjusted operating margin to 31.1%, an increase of 100 basis points from last year.
“I am pleased with the Bio-Techne team’s continued execution in a stabilizing operating environment,” said Kim Kelderman, President and Chief Executive Officer. “For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma.”
Within the business, the Protein Sciences segment—which provides specialized proteins and platforms used in protein analysis—recorded a 2% increase in revenue to $215.1 million. By contrast, revenue in the Diagnostics and Spatial Biology segment declined 4% to $81.2 million.
On a GAAP basis, earnings per share improved to $0.24 from $0.22 in the same quarter last year. The company also pointed to solid commercial execution in China and the broader Asia-Pacific region, which delivered growth for a third straight quarter, alongside improving trends in biotech customers and signs of stabilization among U.S. academic institutions.